Publication Name	World Journal of Gastroenterology
Manuscript ID	40269
Country	Germany

Received	2018-06-11 09:45
Peer-Review Started	2018-06-12 01:16
To Make the First Decision	2018-07-04 01:19
Return for Revision	2018-07-06 02:49
Revised	2018-07-29 10:25
Second Decision	2018-07-31 12:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-08-01 04:23
Articles in Press	2018-08-01 04:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-17 01:03
Publish the Manuscript Online	2018-09-20 02:33

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
Manuscript Source	Invited Manuscript
All Author List	Matthias Ocker
ORCID	Author(s) ORCID Number Matthias Ocker http://orcid.org/0000-0001-8263-6288
Funding Agency and Grant Number
Corresponding Author	Matthias Ocker, MD, Professor, Department of Translational Medicine Oncology, Bayer AG, Muellerstrasse 178, Berlin 13353, Germany. matthiasocker@gmail.com
Key Words	Hepatocellular carcinoma; Biomarker; Next-generation sequencing; Liquid Biopsy; Functional imaging; Molecular imaging; Circulating free DNA; Circulating tumor cells; Immune checkpoint inhibitors
Core Tip	Hepatocellular carcinoma (HCC) is a hetero­geneous disease with various underlying etiologies and an overall still poor prognosis. Biomarkers to identify optimal treatment for distinct patients are still lacking for HCC due to limited availability of biopsies. Novel treatment options, esp. immune checkpoint inhibitors, may need novel bio­marker approaches and non-tissue based technologies might provide a solution to identify those biomarkers. In this article, the current status of biomarker identification for HCC is discussed.
Publish Date	2018-09-20 02:33
Citation	Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979
URL	http://www.wjgnet.com/1007-9327/full/v24/i35/3974.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i35.3974

Full Article (PDF)	WJG-24-3974.pdf
Manuscript File	40269-Review.docx
Answering Reviewers	40269-Answering reviewers.pdf
Audio Core Tip	40269-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	40269-Conflict-of-interest statement.pdf
Copyright License Agreement	40269-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	40269-Language certificate.pdf
Peer-review Report	40269-Peer-review(s).pdf
Scientific Misconduct Check	40269-Scientific misconduct check.pdf
Scientific Editor Work List	40269-Scientific editor work list.pdf